Your browser doesn't support javascript.
loading
Lichenoid Drug Eruption Secondary to Adalimumab: A Case Report.
Alkheraiji, Asma; Alotaibi, Hend; Irfan Thalib, Husna.
Afiliación
  • Alkheraiji A; College of Medicine: Dermatology, Majmaah University, Riyadh, SAU.
  • Alotaibi H; Dermatology, King Saud Medical City, Riyadh, SAU.
  • Irfan Thalib H; College of Medicine: General Medicine and Surgery, Batterjee Medical College, Jeddah, SAU.
Cureus ; 16(7): e64013, 2024 Jul.
Article en En | MEDLINE | ID: mdl-39114193
ABSTRACT
Adalimumab, an anti-tumor necrosis factor-α (TNF-α), is widely prescribed for many autoimmune diseases and chronic inflammatory skin diseases such as hidradenitis suppurative, psoriasis, etc. We report a case of lichenoid drug eruption secondary to adalimumab, a rare side effect, in a 62-year-old female with ulcerative colitis. The skin eruption appeared two weeks after initiating adalimumab. A skin biopsy was taken, and the histopathological findings correlated with a lichenoid drug eruption. Although rare, drug-induced lichen planus has been associated with adalimumab. Early recognition and a high index of suspicion are key in the prompt management of these cases. The discontinuation of adalimumab must be carefully weighed against its therapeutic benefits, as the discontinuation might trigger a severe form of inflammation in the primary autoimmune disease being treated. Extreme caution, early intervention, and a multidisciplinary approach are best for the overall well-being and optimal care of the individual.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article